《现代医学与健康研究》编辑部官网!【中国医师协会系列期刊】
曲美他嗪联合瑞舒伐他汀在稳定型心绞痛患者治疗中的应用研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R541.4

基金项目:

项目名称:湖南省卫生计生委科研计划课题项目(编号:C2016012)


Application study of Trimetazidine combined with Rosuvastatin in the treatment of patients with stable angina pectoris
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 研究曲美他嗪联合瑞舒伐他汀对稳定型心绞痛患者心功能、血脂指标及血液流变学指标的影响。方法 按照随机数字 表法将 2016 年 2 月至 2018 年 2 月湖南省人民医院(湖南师范大学附属第一医院)收治的 102 例稳定型心绞痛患者分成对照组(51 例) 和观察组(51 例)。两组患者均予以常规治疗,对照组患者在常规治疗的基础上予以瑞舒伐他汀进行治疗,观察组患者则在对照组的基 础上联合曲美他嗪进行治疗,均治疗 1 个月。将两组患者治疗后临床疗效,治疗前后心功能指标、血脂指标及血液流变学指标水平进行 比较。结果 治疗后,观察组患者临床总有效率为 88.24%,高于对照组的 70.59%;与治疗前比,治疗后两组患者射血分数(EF)、心 脏指数(CI)、心输出量(CO)、每搏输出量(SV)、血清高密度脂蛋白胆固醇(HDL-C)水平均升高,且观察组高于对照组;与治 疗前比,治疗后两组患者血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平及全血高切黏度、全血低切黏度、 血浆黏度水平均下降,且观察组低于对照组(均P < 0.05)。结论 稳定型心绞痛患者使用曲美他嗪联合瑞舒伐他汀进行治疗,可提高其 临床治疗效果,改善心功能,调节血脂与血液流变学指标水平,治疗效果较为显著。

    Abstract:

    Objective To study the effects of Trimetazidine combined with Rosuvastatin on cardiac function, blood lipid index and hemorheology index in patients with stable angina pectoris. Methods A total of 102 patients with table angina pectoris who were admitted to Hunan Provincial People's Hospital(The First Affiliated Hospital of Hunan Normal University) from February 2016 to February 2018 were divided into the control group (51 cases) and the observation group (51 cases)according to the random number table method. Patients in both groups received conventional treatment, patients in the control group were treated with Rosuvastatin on the basis of conventional treatment, while patients in the observation group were treated with Trimetazidine on the basis of the control group, both groups were treated for 1 month. The clinical efficacy after treatment, cardiac function index, blood lipid index and hemorheology index before and after treatment of patients were compared between the two groups. Results After treatment, the total clinical effective rate in the observation group was 88.24%, which was higher than that 70.59% in the control group; compared with before treatment, the levels of ejection fraction (EF), cardiac index (CI), cardiac output (CO), stroke volume (SV) and high density lipoprotein cholesterol (HDL-C) levels of patients in the two groups increased after treatment , and the observation group was higher than the control group; compared with before treatment, the levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), whole blood high shear viscosity, whole blood low shear viscosity and plasma viscosity of patients in the two groups decreased after treatment, and the observation group was lower than the control group (all P <0.05). Conclusion Trimetazidine combined with Rosuvastatin for the treatment of patients with stable angina pectoris can increase the clinical efficacy, improve cardiac function, regulate the levels of blood lipid and hemorheology index, and the treatment effect is more significant.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-08-23
  • 出版日期:
文章二维码

地址:北京朝阳区北沙滩1号16信箱

邮编:100083

电话:010-64882183 64883630

E-mail:xdyx2020@vip.163.com


温馨提示:建议您使用Chrome80、火狐74+、IE11浏览器 ,当您的浏览器版本过低,可能会影响部分功能正常使用。

现代医学与健康研究 ® 2024 版权所有

技术支持:北京勤云科技发展有限公司